GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Q-linea AB (OSTO:QLINEA) » Definitions » COGS-to-Revenue

Q-linea AB (OSTO:QLINEA) COGS-to-Revenue : 0.82 (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Q-linea AB COGS-to-Revenue?

Q-linea AB's Cost of Goods Sold for the three months ended in Mar. 2025 was kr3.03 Mil. Its Revenue for the three months ended in Mar. 2025 was kr3.68 Mil.

Q-linea AB's COGS to Revenue for the three months ended in Mar. 2025 was 0.82.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Q-linea AB's Gross Margin % for the three months ended in Mar. 2025 was 17.63%.


Q-linea AB COGS-to-Revenue Historical Data

The historical data trend for Q-linea AB's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q-linea AB COGS-to-Revenue Chart

Q-linea AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 132.77 3.68 2.67 0.78 5.70

Q-linea AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.32 18.17 1.90 48.11 0.82

Q-linea AB COGS-to-Revenue Calculation

Q-linea AB's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=13.475 / 2.362
=5.70

Q-linea AB's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=3.032 / 3.681
=0.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Q-linea AB  (OSTO:QLINEA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Q-linea AB's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 3.032 / 3.681
=17.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Q-linea AB COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Q-linea AB's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Q-linea AB Business Description

Traded in Other Exchanges
Address
Dag Hammarskjolds vag 52 A, Uppsala, SWE, SE-752 37
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.

Q-linea AB Headlines

No Headlines